Mark W. Frohlich M.D.
|Age||Total Calculated Compensation||This person is connected to 0 board members in 0 different organizations across 2 different industries.|
Dr. Mark W. Frohlich, M.D. has been an Executive Vice President of Portfolio Strategy at Juno Therapeutics Inc. since February 29, 2016 and served as its Executive Vice President of Research & Development since February 2014. Dr. Frohlich has more than two decades of experience in the field of immuno-oncology. Dr. Frohlich served as the Chief Medical Officer of Dendreon Corp. since January 2008 until February 1, 2014 and as its Executive Vice President of Research and ...
1301 2nd AvenuePhone: 206-256-4545
Seattle, Washington 98101
Board Members Memberships*There is no Board Members Memberships data available.
University of California-San Francisco
Harvard Medical School
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
|Randal J. Kirk J.D.||Chairman and Chief Executive Officer|
|$4.4M||Compensation as of Fiscal Year 2015.|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.